Buscar
Ultragenyx Pharmaceutical Inc
RAREAñadir a la lista de seguimiento
14.510USD
+0.010+0.07%
Cierre 09-17 16:00（ET）
1.43BCap. mercado
PérdidaP/E TTM
Más Datos de Ultragenyx Pharmaceutical Inc Compañía
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product candidates. Its four approved product candidates include Crysvita (burosumab) for the treatment of X-linked hypophosphatemia (XLH), and tumor-induced osteomalacia (TIO), Mepsevii (vestronidase alfa) for the treatment of mucopolysaccharidosis VII (MPSVII) or Sly Syndrome, Dojolvi (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD), and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia (HoFH). Its clinical product candidates include DTX401, DTX301, UX701, UX143, UX111, and GTX-102. UX143 for the treatment of Osteogenesis Imperfecta.
Perfil de Ultragenyx Pharmaceutical Inc
Símbolo de cotizaciónRARE
Nombre de la empresaUltragenyx Pharmaceutical Inc
Fecha de salida a bolsaJan 31, 2014
Director ejecutivoKakkis (Emil D)
Número de empleados1294
Tipo de seguridadOrdinary Share
Fin del año fiscalJan 31
Dirección60 Leveroni Ct
CiudadNOVATO
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal94949
Teléfono14154838800
Sitio Webhttps://www.ultragenyx.com/
Símbolo de cotizaciónRARE
Fecha de salida a bolsaJan 31, 2014
Director ejecutivoKakkis (Emil D)
Ejecutivos de Ultragenyx Pharmaceutical Inc
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.83M
+2.71%
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.83M
+2.71%
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
140.45K
+16.46%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
140.45K
+16.46%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
140.45K
+16.46%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
90.60K
+31.89%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
34.70K
+22.34%
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.83M
+2.71%
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.83M
+2.71%
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Founder, Director
President, Chief Executive Officer, Founder, Director
2.83M
+2.71%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
140.45K
+16.46%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
140.45K
+16.46%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer - Gene Therapy Operations
140.45K
+16.46%
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Ultragenyx Pharmaceutical Inc?
Los cinco principales accionistas de Ultragenyx Pharmaceutical Inc son: Dr. Emil D. Kakkis, M.D., Ph.D.
¿Cuántas instituciones poseen acciones de Ultragenyx Pharmaceutical Inc (RARE)?
A fecha de 2026Q1, 695 instituciones poseen acciones de Ultragenyx Pharmaceutical Inc, con un valor de mercado combinado de aproximadamente 106.19M, lo que representa el 107.82% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -1315399.00.
¿Cuál es la mayor fuente de ganancias de Ultragenyx Pharmaceutical Inc?
El 2026Q1, el segmento empresarial Crysvita royalty revenue generó la ganancia más alta para Ultragenyx Pharmaceutical Inc, ascendiendo a 102.00M y representando el 47.66% de la ganancia total.